EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Luciano J Costa iD, Nizar J Bahlis, Aurore Perrot iD, Ajay K Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu und 33 weitere

New England Journal of Medicine · 19.02.2026 · 394 (8) · 739-752

DOI: 10.1056/nejmoa2514663 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.02.2026. Verfasst von Luciano J Costa und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaNeoplasm Recurrence, LocalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedBortezomibDexamethasoneKaplan-Meier EstimateProgression-Free SurvivalThalidomideDrug Resistance, NeoplasmTime FactorsInjections, Subcutaneous

Substanzen

Antibodies, BispecificAntibodies, MonoclonalBortezomibdaratumumabDexamethasonepomalidomideThalidomide

Autor:innen und Institutionen

  • Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham.
  • Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
  • Universite de Toulouse, Centre Hospitalier Universitaire, Service d'Hematologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Cancer Research Center of Toulouse, Toulouse, France.
  • Emory University, Winship Cancer Institute, Atlanta.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing.
  • Royal Marsden NHS Foundation Trust, London.

ORCID-Profile: Luciano J Costa, Aurore Perrot

Förderung

  • NCI NIH HHS
  • Johnson & Johnson

Zitieren

APA

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., …, & MajesTEC-3 Trial Investigators (2026). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 394(8), 739-752. https://doi.org/10.1056/nejmoa2514663

Vancouver

Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2026;394(8):739-752. doi:10.1056/nejmoa2514663

BibTeX
@article{Costa2026,
  author = {Costa, Luciano J and Bahlis, Nizar J and Perrot, Aurore and Nooka, Ajay K and Lu, Jin and Pawlyn, Charlotte and Mina, Roberto and Caeiro, Gaston and Kentos, Alain and Hungria, Vania and Reece, Donna and Niu, Ting and Mylin, Anne K and Hansen, Charlotte T and Teipel, Raphael and Besemer, Britta and Dimopoulos, Meletios A and Zamagni, Elena and Yoshihara, Satoshi and Kim, Kihyun and Min, Chang Ki and Geerts, Paul and Van Leeuwen-Segarceanu, Elena and Tyczynska, Agata and Reguera, Juan Luis and Johansson, Magnus and Hansson, Markus and Turgut, Mehmet and Grey, Mark and Sidana, Surbhi and Rodriguez-Otero, Paula and Martinez-Lopez, Joaquin and Hashmi, Hamza and Carson, Robin and Kobos, Rachel and Sun, Weili and Lantz, Kristen and Seifert, Anne and Briseno-Toomey, Deborah and O'Rourke, Lisa and Rubin, Maria and Vieyra, Diego and Kang, Lijuan and Mateos, Maria Victoria and MajesTEC-3 Trial Investigators, MajesTEC-3 Trial Investigators},
  title = {Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {8},
  pages = {739--752},
  doi = {10.1056/nejmoa2514663}
}
Kostenlos starten →